<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138901</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2019-01</org_study_id>
    <nct_id>NCT04138901</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesic Effect of Subcostal TAPB for Laparoscopic Gastrectomy</brief_title>
  <official_title>Ultrasound-guided Subcostal Transversus Abdominis Plane Block in Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy: A Randomized Controlled Double-blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, single blinded study is designed to evaluate the postoperative&#xD;
      analgesic efficacy of the ultrasound-guided subcostal transversus abdominis plane block in&#xD;
      gastric cancer patients undergoing laparoscopic gastrectomy. We hypothesize that US guided&#xD;
      subcostal TAP block with ropivacaine can significantly reduce postoperative opioid comparison&#xD;
      in patients with laparoscopic gastrectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients undergoing elective laparoscopic gastrectomy are randomly allocated to receive&#xD;
      subcostal TAP block (n=56) or not (n=56), in addition to a standard postoperative analgesic&#xD;
      regimen comprising of IV fentanyl-based patient-controlled analgesia (PCA) and NSAIDs as&#xD;
      required. At the end of surgery, the TAP group patients will receive bilateral subcostal TAP&#xD;
      block under ultrasound guidance with 15ml of 0.375% ropivacaine bilaterally. Each patient was&#xD;
      assessed by a blinded investigator at 6, 12, 24, and 48 h postoperatively. The primary&#xD;
      outcome is total fentanyl consumption at 24 h after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Actual">June 7, 2020</completion_date>
  <primary_completion_date type="Actual">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective randomized double-blinded study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>We plan to perform TAPB in patients under general anesthesia. Physicians not involved in this study will investigate the outcomes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total fentanyl consumption during 24 hours</measure>
    <time_frame>postoperative 24 hours</time_frame>
    <description>postoperative cumulative fentanyl consumption (mcg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total fentanyl consumption</measure>
    <time_frame>postoperative 6, 12, 48 hours</time_frame>
    <description>postoperative cumulative fentanyl consumption (mcg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score</measure>
    <time_frame>postoperative 6, 12, 24, 48 hours</time_frame>
    <description>11-pointed NRS pain score at resting/coughing NRS (0-10): 0, &quot;no pain&quot;; 10, &quot;worst pain imaginable&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of opioid-related side effects</measure>
    <time_frame>postoperative 6, 12, 24, 48 hours</time_frame>
    <description>Incidence of postoperative nausea and vomiting, dizziness, sedation, respiratory depression (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue nonopioid(ketorolac, nefopam) analgesic requirement</measure>
    <time_frame>postoperative 6, 12, 24, 48 hours</time_frame>
    <description>Overall postoperative rescue of nonopoioid(ketorolac, nefopam) analgesic requirement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving bilateral subcostal TAP block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients not receiving bilateral subcostal TAP block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound guided subcostal transversus abdominis plane block (TAPB)</intervention_name>
    <description>At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.</description>
    <arm_group_label>Group T</arm_group_label>
    <other_name>TAP block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.75% Injectable Solution</intervention_name>
    <description>0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)</description>
    <arm_group_label>Group T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)</intervention_name>
    <description>0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)</description>
    <arm_group_label>Group T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled to undergo elective laparoscopic gastrectomy under general&#xD;
             anesthesia&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical classification I-III&#xD;
&#xD;
          -  Consent to IV-patient controlled analgesia use&#xD;
&#xD;
          -  Willingness and ability to sign an informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Do not understand our study&#xD;
&#xD;
          -  Allergies to anesthetic or analgesic medications&#xD;
&#xD;
          -  Wound infiltration analgesia for postoperative pain control&#xD;
&#xD;
          -  Infection or anatomic abnormality at the needle insertion site&#xD;
&#xD;
          -  Pregnancy/Breast feeder&#xD;
&#xD;
          -  Medical or psychological disease that can affect the treatment response&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hojin Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>KS013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hojin Lee, MD</investigator_full_name>
    <investigator_title>Clinical assistant professor</investigator_title>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Stomach neoplasms</keyword>
  <keyword>Nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

